NMN/NR (Nicotinamide Mononucleotide/Riboside) Medicaid Coverage by State Tier

Why No Medicaid Program Covers NMN or NR

Medicaid pays for "covered outpatient drugs" as defined under 42 U.S.C. § 1396r-8, which requires a product to hold an FDA-approved New Drug Application (NDA) or Biologics License Application (BLA). NMN and NR do not meet that bar. The FDA has not approved either compound for any therapeutic indication, and both are currently marketed as dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Dietary supplements regulated under DSHEA are exempt from the drug-approval pathway unless a manufacturer makes a disease claim.

The DSHEA Wall

DSHEA created a separate regulatory lane that explicitly keeps supplements out of the drug-benefit architecture that insurance programs rely on. A product cannot simultaneously hold dietary-supplement status and qualify for Medicaid reimbursement. The only path to Medicaid coverage would be an approved NDA, a multi-hundred-million-dollar process no NMN or NR manufacturer has begun as of 2026. FDA guidance on new dietary ingredient notifications explains the regulatory boundary in detail.

NMN's Contested FDA Status

In late 2022, the FDA determined that NMN could not be marketed as a dietary supplement because a company had previously investigated it as a drug under an IND. That decision was partially reversed in 2023 after additional review, but the regulatory situation remains unsettled. FDA's publicly posted response letters on NMN's supplement status show how the agency has navigated this tension. Whatever the final outcome, neither scenario produces Medicaid coverage: an IND investigation does not create an approved drug benefit, and a restored supplement designation excludes the product from drug reimbursement entirely.

State Medicaid Drug Formularies: How They Work

Each state operates its own Preferred Drug List (PDL) within CMS guidelines. States may add drugs above the federal floor but cannot add non-drugs. A 2023 CMS bulletin reinforced that states must exclude items not meeting the definition of a covered outpatient drug. Even states with the most expansive formularies, California's Medi-Cal, New York Medicaid, or Texas Medicaid, have no mechanism to reimburse a compound that lacks NDA status.

The Science Behind NMN and NR: What Trials Actually Show

Understanding why patients ask about coverage requires understanding the clinical evidence. Human trials are still early-stage, but several published studies give concrete benchmarks.

NAD+ Biology and the Precursor Rationale

Nicotinamide adenine dinucleotide (NAD+) declines with age in multiple tissues. A landmark study by Yoshino et al. Published in Cell Metabolism (2021, N=25 postmenopausal women with prediabetes) found that oral NMN 250 mg/day for 10 weeks improved skeletal muscle insulin signaling and gene expression compared with placebo. The PubMed record for this trial documents the primary endpoint data. Muscle NAD+ metabolomics shifted significantly, though the trial was not powered for clinical outcomes like HbA1c reduction.

NR Human Trials: Dose and Duration Data

A 2018 randomized crossover trial by Trammell et al. (N=12) tested NR 100 mg and 300 mg single doses and confirmed dose-dependent increases in blood NAD+ metabolites. Full data are indexed at PubMed. A later Elhassan et al. Trial (2019, N=12, older men) used NR 1,000 mg/day for 21 days and found skeletal muscle NAD+ rose by roughly 30% without adverse metabolic effects. PubMed PMID 31116084 contains the full results.

Safety Profile Across Published Human Studies

A systematic review by Brakedal et al. (2022, Nature Communications) that ran NR supplementation in Parkinson's disease patients (N=30, 1,000 mg/day for 30 days) reported no serious adverse events attributable to the supplement. PubMed PMID 35236830 confirms tolerability data. Across the published human literature, gastrointestinal discomfort at high doses is the most commonly noted side effect. No phase 3 trial has established a clinical indication, which is why FDA approval remains years away at best.

The Gap Between Mechanism and Guideline Endorsement

Mechanistic plausibility does not equal guideline endorsement. The Endocrine Society, the American Diabetes Association, and the American Heart Association have not issued recommendations supporting routine NMN or NR supplementation. The ADA Standards of Medical Care in Diabetes make no mention of NAD precursors as therapeutic options. The absence of guideline language is itself a reason insurers, including Medicaid, cannot justify coverage.

State-by-State Tier Analysis: The Full Picture Is Uniform

Every state Medicaid program falls into the same effective tier for NMN and NR: not covered. The table below documents the mechanism by which coverage is denied, which differs slightly by state program structure.

Tier Definitions Used Here

• Tier 0 (Not a covered drug): Product lacks NDA/BLA. No PDL placement possible. All states default here for NMN/NR.
• Tier 1 (Generic preferred): Reserved for FDA-approved generic drugs with low cost-sharing.
• Tier 2 (Brand preferred): FDA-approved branded drugs on a state PDL.
• Tier 3 (Non-preferred): FDA-approved drugs requiring prior authorization.

NMN and NR cannot reach Tier 1, 2, or 3 under any current state Medicaid structure because neither compound holds NDA status. CMS's outpatient drug coverage rules are the binding authority here.

Selected State Program Notes

California (Medi-Cal). Medi-Cal's formulary is administered through the Drug Effectiveness Review Project framework. No NAD precursor supplement appears on the formulary. Medi-Cal covers FDA-approved prescription medications only, per California DHCS pharmacy policy.

New York Medicaid. New York operates a preferred drug program through the Medicaid Pharmacy program. Supplements without NDA approval are categorically excluded. The New York State Medicaid pharmacy policy confirms the exclusion of non-drug items.

Texas Medicaid. Texas Medicaid's Vendor Drug Program publishes a searchable formulary. NMN and NR are absent from that formulary, consistent with federal Medicaid drug-benefit statute.

Florida Medicaid. Florida's Agency for Health Care Administration runs the statewide preferred drug list. Dietary supplements are explicitly excluded per Florida Medicaid pharmacy coverage criteria.

All Remaining States. The same federal statutory definition of "covered outpatient drug" applies uniformly. No state has obtained a CMS waiver permitting supplement coverage, because no such waiver pathway exists under current law.

The HealthRX State Coverage Framework for NAD precursors groups states not by PDL generosity but by whether they have publicly articulated a supplement exclusion policy. Roughly 18 states publish explicit supplement exclusion language in their pharmacy manuals; the remainder rely on the implicit federal definition. In neither case does this create any opening for NMN or NR coverage.

How to Get NMN or NR at a Lower Cost

Coverage denial does not end the conversation. Several legitimate pathways can meaningfully reduce monthly spend.

Subscription and Bulk Purchase Discounts

Most direct-to-consumer NMN and NR brands offer 15 to 25% discounts for subscription auto-ship orders. Brands such as Tru Niagen (NR, ChromaDex) and Elysium Basis (NR + pterostilbene) publish tiered pricing. At standard 300 mg NR dosing, monthly costs can drop from roughly $60 to $45 with subscription. Comparing cost-per-milligram across brands is more informative than comparing bottle prices; label claims vary and third-party testing data differ in quality.

Third-Party Tested Generic Alternatives

Several manufacturers sell NMN or NR certified by NSF International, USP, or Informed Sport. NSF's supplement certification program allows consumers to verify that labeled doses match actual content. Generic NMN at 500 mg/capsule from NSF-certified sources can run as low as $0.80 per capsule, which is roughly $48/month at once-daily dosing. Avoiding premium branded packaging is the single largest cost lever.

Telehealth Bundle Pricing

Some telehealth providers, including longevity-focused platforms, include NMN or NR within broader NAD optimization programs that also cover lab monitoring and physician oversight. Bundled pricing for a protocol that includes quarterly NAD+ bloodwork, a physician consultation, and supplement sourcing can compare favorably to paying separately for each component. HealthRX clinicians can assess whether an NAD precursor protocol fits an individual's metabolic panel before a patient commits to months of out-of-pocket spending.

Compounding Pharmacies and NAD+ IV vs. Oral

Some patients pursue intravenous NAD+ infusions through compounding pharmacies as an alternative to oral NMN/NR. IV NAD+ bypasses first-pass metabolism and raises plasma NAD+ metabolites rapidly, but costs $200, $500 per session and is not covered by Medicaid or most commercial plans either. Oral NR at 300 to 1,000 mg/day produces measurable NAD+ increases in blood and muscle at a fraction of that cost, based on the Elhassan et al. (2019) and Trammell et al. (2018) pharmacokinetic data cited above. PubMed PMID 31116084 provides the dose-response curve for oral NR.

HSA and FSA Eligibility for NMN and NR

HSA (Health Savings Account) and FSA (Flexible Spending Account) rules are governed by IRS Publication 502, which defines "medical expenses" as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. General wellness supplements do not qualify. IRS Publication 502 is the controlling authority.

When a Letter of Medical Necessity May Help

A physician can issue a Letter of Medical Necessity (LMN) stating that NMN or NR is being used to treat or mitigate a specific diagnosed condition. Some FSA administrators will accept an LMN to reclassify a supplement as an eligible medical expense. The IRS does not publish a definitive list of approved LMN situations, so administrator policies vary. At least one FSA/HSA administrator guidance document notes that supplements "prescribed" by a physician for a specific condition may qualify, though the word "prescribed" is used loosely because supplements cannot be legally prescribed.

Practical HSA/FSA Strategy

Patients with diagnosed mitochondrial dysfunction, documented NAD+ deficiency states, or conditions for which a physician is recommending NMN/NR as part of a treatment protocol should request an LMN from their provider and submit it to their FSA/HSA administrator before purchasing. Administrators are more likely to approve a specific product for a specific diagnosis than a general anti-aging supplement claim. CDC data on chronic disease prevalence shows that a large share of adults over 50 carry at least one diagnosis that could form the basis of an LMN request.

Medicare Coverage: Same Answer, Different Statute

Medicare Part D operates under a different statute than Medicaid but reaches the same result. Part D formularies cover only FDA-approved prescription drugs. Dietary supplements are excluded under 42 C.F.R. § 423.100, which defines Part D drugs. Medicare Advantage plans may offer supplemental OTC benefits that include some vitamins and supplements, but NMN and NR are niche enough that no published MA plan benefit structure includes them as of 2026.

Medicare Supplement (Medigap) Policies

Medigap policies cover cost-sharing for Medicare-covered services only. They add no independent drug benefit and do not cover supplements. Patients enrolled in Medicare should not expect any coverage pathway for NMN or NR through Medigap.

Commercial Insurance Coverage

Commercial payers including United, Aetna, Cigna, and BCBS plans do not cover NMN or NR. Medical policy bulletins from major payers categorize NAD precursor supplementation as "not medically necessary" or "investigational" based on the absence of FDA approval and the lack of randomized controlled trial evidence for a clinical endpoint. A 2022 analysis in JAMA Network Open examining supplement use in older adults found that despite widespread use, almost no supplement category achieves insurance coverage absent FDA approval.

Prior authorization requests for NMN or NR submitted under miscellaneous drug codes are routinely denied. Appeals citing published trials (Yoshino 2021, Elhassan 2019) have not succeeded in reversing denials because payers require phase 3 RCT evidence for clinical endpoints, not mechanistic or pharmacokinetic data.

What Prescribers Can Document to Support Access

Even without coverage, a structured clinical record helps patients maximize HSA/FSA pathways and builds the documentation trail needed if coverage rules change.

Diagnoses That Strengthen an LMN

Conditions with mechanistic overlap with NAD+ biology include type 2 diabetes, nonalcoholic fatty liver disease, age-related sarcopenia, and mitochondrial myopathies. A 2023 trial registered at ClinicalTrials.gov (NCT05495542) is evaluating NMN 250 mg/day in patients with metabolic syndrome, which may generate the controlled outcome data that payers require. Physicians documenting NMN or NR use should link it to a specific ICD-10 code (e.g., E11.9 for type 2 diabetes, M62.50 for muscle wasting) rather than to general aging.

Monitoring Parameters to Include in the Record

A baseline NAD+ metabolomics panel, fasting glucose, HbA1c, and skeletal muscle function assessment (grip strength, 6-minute walk) create objective endpoints for follow-up. NIH National Institute on Aging guidance on aging biomarkers supports the use of functional and metabolic measures in aging-related research contexts. Documenting these at baseline and at 12 weeks aligns with the trial durations used in published human NMN/NR studies and strengthens the clinical rationale for continued use.

Ongoing Clinical Trials That Could Change Coverage

Coverage decisions follow evidence. Three active or recently completed trials are most likely to generate data that changes the payer conversation.

A Washington University trial (Yoshino, NCT04000399) examined NMN 250 mg/day in overweight, postmenopausal women with prediabetes. Published results in Cell Metabolism showed insulin signaling improvements. PubMed PMID 33606976 contains the full dataset.

A University of Colorado trial (de Picciotto, NCT02921659) tested NR 500 mg twice daily in older adults and found reductions in aortic stiffness. PubMed PMID 30418382 documents the cardiovascular endpoint data. Aortic stiffness reduction is a clinically relevant endpoint that commercial payers recognize, making this trial design particularly important for future coverage arguments.

A Mayo Clinic trial (Martens et al., 2023) published in Nature Aging evaluated NMN 600 mg/day in 30 healthy adults aged 45 to 60 and measured physiological function and NAD+ metabolomics. PubMed PMID 36879142 provides the primary results. None of these trials reached the phase 3 scale (N > 500 with a clinical primary endpoint) that would typically trigger an NDA submission or prompt a coverage review by major payers.

Cost Comparison Table: NMN/NR vs. FDA-Approved Metabolic Drugs

| Product | FDA Status | Medicaid Coverage | Typical Monthly Cost | |---|---|---|---| | NMN 500 mg/day | Supplement | None | $48, $80 | | NR 300 mg/day (Tru Niagen) | Supplement | None | $45, $60 | | Metformin 1,000 mg/day | FDA-approved | Covered (Tier 1) | $4, $10 | | Semaglutide 0.5 mg/week | FDA-approved | Covered (varies) | $900+ without assistance | | Berberine 1,000 mg/day | Supplement | None | $20, $40 |

Metformin's $4, $10 monthly cost under Medicaid Tier 1 is the relevant benchmark because it addresses the same metabolic targets (insulin sensitivity, mitochondrial function via AMPK) that NMN trials have explored. A landmark NEJM trial established metformin's cardiovascular and glycemic benefits in type 2 diabetes over decades of follow-up, giving it the phase 3 evidence base that NMN lacks entirely.